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Abstract
Background: This research assesses knowledge amongst drug deliverers about the implementation of mass drug
administration (MDA) for lymphatic filariasis (LF) in Agam District (West Sumatera Province), the City of Depok (West
Java Province) and the City of Batam (Kepulauan Riau Province), Indonesia.
Methods: A cross-sectional survey was conducted from January to March 2015 at these three sites. Respondents
were identified using purposive sampling (i.e. cadre, health worker or community representatives). A total of 318
questionnaires were accepted for analysis. Three outcomes were assessed: knowledge about LF; knowledge about
MDA implementation; and was informed about MDA coverage. Logistic regression analyses were employed to
examine factors associated with these three outcomes.
Results: Less than half of respondents were charactersised as having a high level of LF knowledge and less than
half a high level of knowledge about MDA. The odds of having a high level of knowledge of LF was significantly
lower in Batam City than Agam District, yet higher amongst health workers than cadres. Deliverers living in urban
areas reported more feedback on MDA outcomes than in the rural district. Health workers received more feedback
than cadres (P < 0.001). Deliverers perceived the difference between coverage (drug receipt) and compliance (drug
ingestion) in the community.
Conclusions: There are variations in knowledge about LF and MDA as well as feedback across drug deliverers in
MDA across geographical areas. Adaptation of the MDA guidelines, supportive supervision, increasing the availability
of supporting materials and directly-observed therapy might be beneficial to improve coverage and compliance in
all areas.
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Background
Lymphatic filariasis (LF) is one of the oldest parasitic dis-
eases in the world [1]. Although it does not kill, LF dis-
ables individuals with its long-term clinical manifestations
which can also result in economic and social conse-
quences [2]. To date, more than 120 million people in 81
countries are infected globally and more than one billion
people continue to live in areas at risk for infection [1].
In Indonesia, LF remains an important public health
problem. Efforts to eliminate LF in Indonesia have been
conducted since 1975, especially in highly endemic areas
[3]. Indonesia is the only country in the world with three
types of LF parasite: Wuchereria bancrofti, Brugia
malayi and Brugia timori. It was estimated that in 2016,
29 provinces and 239 cities/districts were LF endemic
areas, and thereby 102,279,739 people living in those
areas were at risk of infection with LF [4].
In 2000, the Global Programme to Eliminate LF (GPELF)
was established by the World Health Organization, with a
target of LF elimination by 2020 [1]. GPELF uses a two-
pronged approach, combining mass drug administration
(MDA) for all those eligible in at risk populations [5] with
assistance for those with lymphedema and elephantiasis to
reduce LF morbidity and suffering [1]. It is thought that
MDA given for long enough, at high enough coverage and
adherence (compliance) will be sufficient to interrupt trans-
mission and eliminate the parasite [1, 6, 7]. Districts are
deemed eligible for MDA if they have greater than 1%
microfilaria prevalence (mf) in the total population [1].
Indonesia has been participating in the global LF elimin-
ation programme since April 2002 using a district or city as
its implementation unit [8]. Presidential Regulation No. 7
Year 2005 listed the elimination of LF as a national priority
for controlling infectious diseases [9].
One of the key components in the Indonesian MDA
programme is the use of community drug distributors,
called cadres in Indonesia, working together with health
personnel in the village for the delivery of the LF drugs.
Within the Indonesian context, cadres play an important
role in the health of the village. Each village in Indonesia
will have several cadres who are responsible for maternal
and child health activities as well as any additional health
activities planned in the village. They are renumerated
with a small stipend for their activities.
Globally, research has shown the important role
community drug deliverers (CDDs) play in the LF drug
distribution [10]. As members of the community, they
know how to reach people effectively and have been
shown to improve community compliance with taking
the LF drugs. In Indonesia they are specifically respon-
sible for disseminating information about LF before
MDA, drug delivery and reporting activities related to
MDA. They work closely with the local health staff from
the primary health care center (called Puskesmas in
Indonesia) who are responsible for their training and
supervision.
Despite all the efforts and gains that Indonesia has made
in the LF elimination programme, achieving consistent
and sufficient coverage (drug receipt) and compliance
(drug ingestion) remains a challenge across many of the
provinces in Indonesia [11]. This is a major concern as the
2020 deadline approaches for LF elimination [1]. One rea-
son lies in the coverage - compliance gap that occurs in
situations where directly observed treatment (DOT) is not
implemented, meaning that drugs that are distributed are
recorded as consumed, when actual consumption has not
been confirmed by the distributor [12]. A complementary
study to this one highlighted a coverage-compliance gap
in the data reported in two of the study districts discussed
in this paper [13]. The district health teams expected that
all drugs distributed were consumed, however follow up
research showed that only a proportion of recipients actu-
ally consumed the distributed LF drugs [13]. According to
the international guidelines, LF drugs should be consumed
using DOT [14]. In the Indonesian context, this would
mean taking the pills in front of the cadres or the frontline
health personnel. As the Indonesian program accelerates
towards elimination, ensuring DOT will be important to
ensuring effective MDA, i.e. that distributed drugs are
consumed drugs.
In 2015, research was carried out in Indonesia by the
Center for Health Research in the Faculty of Public Health
at Universitas Indonesia in partnership with researchers
from the USA, Canada and Australia, to assess coverage and
compliance in three districts and to increase understanding
as to why drug coverage may be persistently low, what spe-
cific actions may be undertaken to improve delivery and up-
take and how those responsible for delivering MDA may be
better supported. The research described here complements
a community-based study using micro narratives [13] and
was performed in the same catchment areas, i.e. the City of
Depok (West Java Province), the City of Batam (Kepulauan
Riau Province) and Agam District (West Sumatera Prov-
ince). The research tool used here also included micro nar-
ratives; however, they are not presented here in the analysis.
Using data from this research, this paper aims to assess
knowledge about LF and the implementation of MDA for
LF amongst drug deliverers in those three districts/cities of
Indonesia. Understanding how drug distributors participate
in MDA, know the eligibility criteria and retain basic
scientific knowledge will be important so that elimination
programs know how to better support improvements to
program reach, particularly in areas of low coverage.
Methods
Data source and study sites
The study used information from a cross-sectional survey
conducted from January to March 2015 in one district and
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two cities of Indonesia: Agam District (West Sumatera
Province), the City of Depok (West Java Province) and the
City of Batam (Kepulauan Riau Province) (Fig. 1). Based on
the recommendation from the national LF Elimination
Programme, Ministry of Health, Republic of Indonesia,
these three areas were proposed due to persistent chal-
lenges in the implementation of the previous MDA rounds.
In 2015 when the surveys were implemented, Agam
District and the City of Depok had been actively working to
improve their MDA since baseline surveys in 2014. This
study reflects the baseline results for the City of Batam.
Background information of study sites
Agam District, located on the western coast of West
Sumatera Province, has a population of just over 450,000
based on the 2010 Population Census [15] which was
distributed over 2300 km2 (190 people per km2). The
primary economic activity is agriculture. The LF species in
this area is Brugia malayi [11]. In 2014, the microfilaria
(mf) prevalence in Agam District ranged between 7.3–8.
7% [16]. Mass drug administration began in 2005 with
partial geographical coverage. In 2007, the district was
implementing MDA across the whole district. At the time
of this research (2015), the District Health Authority in
Agam had conducted five rounds across the whole district
(i.e. full geographical coverage). According to information
from District Health Office of Agam, drug coverage
ranged between 89.6–96.7% in 2015.
The City of Depok is part of the greater metropolitan
area of Indonesia known as Jabodetabek (Jakarta, Bogor,
Depok, Tangerang and Bekasi). Depok is located in West
Java Province, with the population of 1.75 million based
on the 2010 Population Census [17] in an area of 200
km2 (8746 people per km2). In 2007, the mf prevalence
was measured at 2.8% in a population of 500 people. In
2012, the mf prevalence in Depok was 2.01% [18]. The
LF species in this area is Wuchereria bancrofti. The City
of Depok began MDA in 2006 with partial geographical
coverage. By the time this research began in 2013, the
City of Depok had completed five rounds of MDA at full
geographical coverage, with coverage varying between
46–84%, as per district records.
The City of Batam is the largest city in Riau Islands
Province, located across the strait of Singapore. The total
population of Batam based on the 2010 Population
Census was 944,285 people, with population density of
940 people/km2. As an industrial city, Batam is included
in the free-trade zone Indonesia-Malaysia-Singapore
Growth Triangle. The LF species in this area is Brugia
malayi. According to information from the Health Office
of Batam City, by 2016, Batam had conducted MDA five
times since 2013 and the coverage during this time were
between 51.8–73.1%, per district records.
Study design and samples of the study
In each district the research team held consultations with
LF program managers in the Health Office to determine
Fig. 1 Map of study sites
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the best areas for the research. Some sub-districts were
identified as having more challenges related to MDA
coverage than others and as such, they were selected pur-
posively for the research. The sub-districts selected were:
(i) in Agam District: Ampek Nagari, Tanjung Mutiara and
Lubuk Basung; (ii) in the City of Depok: Tapos, Limo,
Bojong Sari, Sukmajaya, Beji; and (iii) in the City of Batam:
Bengkong, Galang, Sagulung.
In each district, two research components were carried
out: a community survey, whose methods and results are
reported in Krentel et al. [13] and a survey administered
to those involved with drug delivery living in the same
sub-districts as the community survey. This paper reports
on the methods and quantitative data from the deliverer
survey. Because health personnel and community leaders
also participate in the MDA together with the cadrers, it
was decided that all three groups should be included in
the sample as “drug deliverers”.
In each district, 100 respondents were selected using
purposive sampling from the hamlet, village and sub-dis-
trict level. The respondents had to have been involved in
the last MDA activity (either in promotion or implementa-
tion), and were identified as cadres from the hamlet level:
village midwives; community or religious leaders (village
level); the head of health center; the local LF program man-
ager; and community or religious leaders (sub-district level).
Survey instruments and field personnel
A questionnaire was designed to allow for broad exam-
ination of factors associated with the MDA process,
namely factors associated with facilitating effective drug
delivery (e.g. training, supervision, incentives, obligation
to superiors); perception of community engagement with
the MDA process; opinions about the LF drugs (e.g. size,
taste, packaging, safety); and respondent’s role in the
MDA (e.g. tasks, perception of self-confidence to carry
out their tasks, perceived importance of their role).
A fieldwork team was established in each district led by
one district field coordinator (DFC) with two local inter-
viewers recruited from each study site. DFCs and enumer-
ators attended a two-day training program followed by a
one-day supervised practice in the field. The training
sought to familiarise respondents with the survey method-
ology, the questionnaires and interview techniques.
Following the training, local enumerators implemented
the survey. At the end of each day of data collection, the
enumerators, field coordinators and members of the
research team reviewed the questionnaires and checked
them for any issues.
The questionnaire had certain similarities with the com-
munity survey conducted concurrently, namely that it
used micronarratives as the basis for better understanding
of the deliverers’ experience. This methodology has been
described elsewhere [13, 19]. The question used to elicit
the deliverer’s experience was, “tell me about one experi-
ence that was your most memorable when you gave the
drugs out or when you were raising awareness about
MDA”. Following that micronarrative, participants were
asked to answer a series of closed explanatory questions
that provided additional insight into the respondent’s
experience. Respondents were also asked a series of ques-
tions eliciting their knowledge of three aspects of LF and
LF delivery (see below for details). This paper presents the
analysis of the explanatory and knowledge questions.
Outcome variables
In this analysis, we used three outcome variables: (i) know-
ledge about LF; (ii) knowledge about MDA implementation;
and (iii) a proxy indicator for feedback in MDA based on
being informed about the number of people taking LF
drugs (MDA feedback). The scores assigned to variables
used to construct each outcome were summed to provide a
total score for each outcome for each respondent. For the
purpose of this analysis all questions were considered to be
of equal weight.
For the oucome variable of “knowledge about LF”, three
variables were used: (i) know that worm is the cause of
LF; (ii) know that mosquitoes transmit LF; and (iii) know
that LF is preventable. A score of 1 was assigned where a
question was answered correctly and 0 otherwise. After
identifying the median distribution of the scores, we cate-
gorized individuals scored less than median as having a
“low level of knowledge”; whereas individuals scored the
same as median or above as having a “high level of know-
ledge” about LF for the purposes of this research.
For the outcome of “knowledge about MDA”, six vari-
ables were used: knowledge that (i) all LF drugs should
be taken; (ii) pregnant women should not take LF drugs;
(iii) children under two years old should not take LF
drugs; (iv) severely undernourished children should not
take LF drugs; (v) people aged more than 75 years-old
should not take LF drugs; and (vi) severely ill people
should not take LF drugs. A score of 1 was assigned to
each question answered correctly and 0 if otherwise.
The total score for this outcome thus ranged from 0 to
6. As with the previous score, using median distribution
of respondents’ scores as the cut-off point, individuals
scored less than median was considered as having a “low
level of knowledge” and individuals scored the same as
median or above as having a “high level of knowledge”
about MDA for the purposes of this research.
For the outcome variable of “MDA feedback”, the vari-
able was based on one question about whether respondent
was informed about the number of people who received
or took LF drugs. Score 1 was assigned to respondent who
answered “yes” and score 0 otherwise. This score repre-
sented the feedback received by the deliverer about the
outcome of the last MDA.
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Potential predictors
Predictor variables were used to explain or predict the
value of outcome variables. Three groups of predictors
were used: (i) socio-demographic characteristics: district/
city (Agam, Depok, Batam); age of respondents (≤ 35
years, 36–45 years and ≥ 46 years); sex (male and female);
highest level of educational attainment (no school/incom-
plete primary/completed primary school); length of stay in
the area (≤ 2 years, > 2 years); (ii) role and process of de-
livering LF drugs: role of respondents during MDA (cadre,
community/religious leaders, health workers); experience
of working with others during MDA (yes and no); and (iii)
knowledge and training to perform in MDA: perceived
adequacy of knowledge to carry out roles and responsibil-
ities in MDA (inadequate, neutral and adequate); and
perception about training prior to MDA (very informative,
informative, less informative, nothing).
Data analysis
We examined the characteristics of all variables (outcome
variables and potential predictors) using contingency
tables. Logistic regression analyses were used to determine
factors associated with all outcome variables. The esti-
mated measures of association were assessed using ORs
(odds ratios). In the first stage of logistic regression
analysis, bivariate regression analyses were employed to
assess the relationship between outcome variables and
their potential predictors, independently. Afterwards,
multivariate analyses were performed to examine the asso-
ciation between outcome variables and potential predic-
tors. We used backward elimination method to remove all
variables not significantly related to the study outcome
using the significance level of 0.05. The variables district,
age and role of respondent during MDA were selected a
priori and were retained in the final model regardless of
the significance level. In the final model, adjusted ORs
(aOR) and 95% confidence intervals (95% CIs) were
determined for all variables in the model. All estimates
presented in this analysis considered the complex sample
design. We used Stata/MP software (version 13.1; Stata-
Corp) for all analyses. The results of the research have
been presented to the District Health Office in all three
districts as well as the National LF Programme, for their
consideration and input into the analysis in a half-day
workshop in Jakarta.
Results
In this study we interviewed 318 people who had been
involved in delivering LF drugs during the last MDA: 109
from Agam District, 107 from Depok and 102 from Batam.
The distribution of respondents by socio-demographic
characteristics as well as their role and intergration with
other programs when delivering LF drugs during MDA is
shown in Table 1. Around 75% of respondents completed
at least senior high school, 95% stayed in the study area for
more than two years, and more than half of the respon-
dents were cadres. When respondents were asked about
their experience in the last MDA, the majority reported
that almost all community members were aware of the
MDA. Most respondents reported MDA was conducted as
an individual health activity and was not integrated with
other programs. Only 20% of respondents reported integra-
tion with other programs during MDA, the highest in
Depok (29%), followed by Agam (22.9%) and Batam (8.8%).
Frequency distribution of outcome variables by different
characteristics
Across the three sites, 50% or less of respondents inter-
viewed in this study had a high level of knowledge about
LF (Table 1), particularly in the City of Batam, where only
25.5% of respondents had a high level of knowledge about
LF. Figure 2 shows than less than 50% of respondents
were aware that worms were the primary cause of LF.
However, almost 90% of respondents stated that LF is
preventable.
Similarly, less than half of respondents were
assessed as having a high level of knowledge about
MDA (Table 1). Less than half of respondents were
aware that children under two years old, person aged
more than 75 years and undernourished children were
not eligible to take LF drugs (Fig. 3). Nevertheless,
more than 75% of LF drugs deliverers stated that
their knowledge was already adequate to help them
conduct their work. A majority of deliverers surveyed
also perceived that the information they received was
sufficient to help them perform their tasks and
responsibilities during MDA (Table 2).
On average, 65% of drugs deliverers across all study
sites claimed that they had been informed about the
number of people who received or swallowed the LF
drugs at the end of the last MDA (MDA feedback)
(Table 1). About 86% of respondents perceived that
many people had received the LF drugs in the last MDA;
however when asked about their perception of those
who had swallowed the pills, only 71% reported that
“many people had taken them” (Fig. 4).
By role during MDA, the distribution of respondents
differed between the three outcome variables as shown
in Table 2. The highest proportion of deliverers who had
a high level of knowledge of LF, MDA and feedback
about MDA were health workers (i.e. village midwives,
head of health center, LF program manager), and
followed by cadres (Fig. 5). The proportion of health
workers with a high level knowledge about MDA was
still below 70%, whereas the proportion of cadres and
community leaders who had a high level of knowledge
about LF and MDA were all below 45% (Fig. 5).
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By study sites, the proportion of respondents who per-
ceived their knowledge was adequate to help them in
carrying out their roles and responsibilities during the
MDA was the highest in Agam District (83.5%) and the
lowest in the City of Batam (66.7%) (Table 3). The City
of Batam also had the lowest proportion of LF drugs
deliverers who had a high level of knowledge about LF
and MDA amongst the three sites.
Table 1 Frequency distribution of drugs deliverers in MDA according to their socio-demographic charateristics, role in MDA and out-
come variables
Variable Frequency (total) High knowledge
about LFa
High knowledge
about MDAb
Received MDA
feedback
n % 95% CI n % 95% CI n % 95% CI n % 95% CI
A. Socio-demographic characteristics
District/City
Agam 109 34.3 29.2–39.7 55 50.5 41.1–59.8 54 49.5 40.2–58.9 53 48.6 39.3–58.0
Depok 107 33.7 28.6–39.1 49 45.8 36.5–55.4 49 45.8 36.5–55.4 85 79.4 70.7–86.1
Batam 102 32.1 27.2–37.4 26 25.5 17.9–34.9 31 30.4 22.2–40.1 70 68.6 58.9–76.9
Age
≤ 35 years 66 20.8 16.6–25.6 28 42.4 31.0–54.7 37 56.1 43.8–67.6 40 60.6 48.3–71.7
36–45 years 138 43.4 38.0–48.9 61 44.2 36.1–52.6 62 44.9 36.8–53.4 93 67.4 59.1–74.7
≥ 46 years 114 35.9 30.7–41.3 41 36.0 27.6–45.2 35 30.7 22.9–39.8 75 65.8 56.6–74.0
Sex
Male 65 20.4 16.3–25.3 18 27.7 18.1–39.9 19 29.2 19.4–41.5 31 47.7 35.8–59.9
Female 253 79.6 74.7–83.7 112 44.3 38.2–50.5 115 45.5 39.4–51.7 177 70.0 64.0–75.3
Education group
No school/incomplete primary school/
completed primary school
25 7.9 5.4–11.4 5 20.0 8.4–40.6 9 36.0 19.6–56.5 11 44.0 25.9–63.8
Completed secondary 51 16.0 12.4–20.5 17 33.3 21.7–47.4 21 41.2 28.5–55.2 33 64.7 50.6–76.7
Completed senior HS 147 46.2 40.8–51.8 56 38.1 30.6–46.3 55 37.4 29.9–45.6 93 63.3 55.1–70.7
Completed college/above 95 29.9 25.1–35.2 52 54.7 44.6–64.5 49 51.6 41.5–61.5 71 74.7 65.0–82.5
Length of stay in the area
≤ 2 years 15 4.7 2.9–7.7 9 60.0 33.9–81.4 6 40.0 18.6–66.1 11 73.3 45.6–90.0
> 2 years 302 95.0 91.9–96.9 120 39.7 34.3–45.4 127 42.1 36.6–47.7 196 64.9 59.3–70.1
B. Experience, role and integration with
other programs during MDA
Role of respondents during MDA
Cadre 175 55.0 49.5–60.5 66 37.7 30.8–45.2 72 41.1 34.1–48.6 112 64.0 56.6–70.8
Community/religious leaders 84 26.4 21.8–31.6 20 23.8 15.8–34.2 23 27.4 18.9–38.0 43 51.2 40.5–61.8
Health workers (village midwives, head
of health centre, LF program manager)
59 18.6 14.6–23.2 44 74.6 61.8–84.2 39 66.1 53.1–77.1 53 89.8 79.0–95.4
Frequency of participation in MDA
1–3 times 170 53.5 47.9–58.9 49 28.8 22.5–36.1 58 34.1 27.3–41.6 101 59.4 51.8–66.6
> 3 times 148 46.5 41.1–52.1 81 54.7 46.6–62.6 76 51.4 43.3–59.4 107 72.3 64.5–79.0
Integration with other program during
MDA
No 253 79.6 74.7–83.7 91 36.0 30.3–42.1 99 39.1 33.3–45.3 159 62.8 56.7–68.6
Yes 65 20.4 16.3–25.3 39 60.0 47.6–71.3 35 53.8 41.6–65.6 49 75.4 63.4–84.4
aKnowledge about LF is based on three variables: (i) know that worm is the cause of LF; (ii) know that mosquitoes transmit LF; and (iii) know that LF is
preventable. Low level of knowledge is assigned to those scoring less than median of the distribution and high level of knowledge is assigned to those scoring
the same as median or above
bKnowledge about MDA is based on six variables: knowledge that (i) all LF drugs should be taken; (ii) pregnant women should not take LF drugs; (iii) children
under two years old should not take LF drugs; (iv) severely undernourished children should not take LF drugs; (v) people aged more than 75 years old should not
take LF drugs; and (vi) severely ill people should not take LF drugs. Low level of knowledge is assigned to those scoring less than median of the distribution and
high level of knowledge is assigned to those scoring the same as median or above
Titaley et al. Parasites & Vectors  (2018) 11:315 Page 6 of 14
Multivariable analysis of the three outcome variables
Table 4 shows the results of the multivariable analyses
aimed to examine factors associated with three outcome
variables used in this study. For the first indicator set, the
odds of having a high level of knowledge about LF was
lower in the City of Batam (aOR = 0.39, 95% CI: 0.– 0.85, P
= 0.017) than in Agam District. As may be expected, the
odds of having a high level of knowledge about LF amongst
health workers were more than six times the odds of cadres
(aOR = 6.47, 95% CI: 3.03–13.83, P < 0.001). Amongst
deliverers reporting that there was no training, the odds of
having high level of knowledge about LF was five times
lower than those who considered the training to be highly
informative (aOR = 0.21, 95% CI: 0.05–0.84, P = 0.027).
Similarly, for the second outcome variable, the odds of
having a high level of knowledge about MDA amongst
Fig. 2 Knowledge of lymphatic filariasis
Fig. 3 Knowledge about MDA
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drugs deliverers aged 46 years and above were about 70%
the odds of those aged 35 years or less (aOR: 0.31, 95% CI:
0.15–0.64, P = 0.002). The odds of having a high level of
knowledge about MDA was more than twice as high in
health workers relative to cadres (aOR: 2.68, 95% CI: 1.
40–5.14, P = 0.003) (Table 4).
For the third outcome variable, our analysis showed that
LF drugs deliverers in the City of Batam were more likely
to be informed (receive MDA feedback) about the number
of people taking LF drugs than in Agam District (aOR: 2.
54, 95% CI: 1.33–4.86, P = 0.005) (Table 4). Female deliv-
erers were also more likely to receive feedback than male
(aOR: 2.68, 95% CI: 1.07–6.75, P = 0.036). As expected,
health workers were nine times more likely to receive
MDA feedback than cadres (aOR: 9.01, 95% CI: 3.32–24.
44, P < 0.001). Drugs deliverers who perceived that their
knowledge to perform their tasks and responsibility in
MDA was adequate, were also more likely to receive feed-
back about community’s compliance in MDA (aOR: 6.72,
95% CI: 2.48–18.22, P < 0.001) than those perceiving that
their knowledge to perform their tasks and responsibility
in MDA was inadequate.
Discussion
Our understanding of the knowledge of community drug
deliverers have about LF and MDA is not well researched
globaly. This paper represents one of a few studies with an
aims to assess the knowledge, perceptions and experiences
of drug deliverers within an LF elimination campaign.
Most of the peer-reviewed literature exploring issues relat-
ing to deliverers has been predominantly based within the
African context [20]. While some of the same issues will
apply to deliverers in the Asian context, others will not.
For example early research established differences in
preferences for MDA delivery in India and Ghana, notably
the involvement of frontline health personnel in India
versus community volunteers in Ghana [21, 22]. The LF
programme in Indonesia exhibits certain characteristics:
Table 2 Frequency distribution of drugs deliverers in MDA according to their knowledge about LF and MDA as well as MDA
feedback by their role during MDA
Variable Frequency (total) role during MDA Cadre (n = 175) Religious/community leader (n = 84) Health workers (n = 59)
n % 95% CI n % 95% CI n % 95% CI n % 95% CI
A. Knowledge about lymphatic filariasis
Knowledge of LFa
Low 188 59.1 53.6–64.4 109 62.3 54.8–69.2 64 76.2 65.8–84.2 15 25.4 15.9–38.2
High 130 40.9 35.6–46.4 66 37.7 30.8–45.2 20 23.8 15.8–34.2 44 74.6 61.8–84.2
B. Knowledge about MDA
Knowledge about MDAb
Low 183 57.6 52.0–62.9 102 58.3 50.8–65.4 61 72.6 62.0–81.2 20 33.9 22.9–47.0
High 134 42.1 36.8–47.7 72 41.1 34.1–48.6 23 27.4 18.9–38.0 39 66.1 53.1–77.1
C. MDA feedback
Informed about the number of people receiving or taking LF drugs
No 110 34.6 29.5–40.0 63 36.0 29.2–43.4 41 48.8 38.2–59.5 6 10.2 4.6–21.0
Yes 208 65.4 60.0–70.5 112 64.0 56.6–70.8 43 51.2 40.5–61.8 53 89.8 79.0–95.4
D. Other
Perceived adequacy of knowledge to carry out roles and responsibilities in MDA
Inadequate 28 8.8 6.1–12.5 13 7.4 4.4–12.4 11 13.1 7.4–22.2 4 6.8 2.5–16.9
Neutral 50 15.7 12.1–20.2 27 15.4 10.8–21.6 15 17.9 11.0–27.6 8 13.6 6.9–25.0
Perception about training received prior to MDA
Very informative 117 36.8 31.6–42.3 56 32.0 25.5–39.3 31 36.9 27.2–47.8 30 50.9 38.2–63.4
Informative 152 47.8 42.3–53.3 94 53.7 46.3–61.0 37 44.1 33.8–54.9 21 35.6 24.4–48.7
Less informative 29 9.1 6.4–12.8 14 8.0 4.8–13.1 10 11.9 6.5–20.8 5 8.5 3.5–19.0
No training 20 6.3 4.1–9.6 11 6.3 3.5–11.0 6 7.1 3.2–15.1 3 5.1 1.6–14.8
aKnowledge about LF is based on three variables: (i) know that worm is the cause of LF; (ii) know that mosquitoes transmit LF; and (iii) know that LF is
preventable. Low level of knowledge is assigned to those scoring less than median of the distribution and high level of knowledge is assigned to those scoring
the same as median or above
bKnowledge about MDA is based on six variables: knowledge that (i) all LF drugs should be taken; (ii) pregnant women should not take LF drugs; (iii) children
under two years old should not take LF drugs; (iv) severely undernourished children should not take LF drugs; (v) people aged more than 75 years old should not
take LF drugs; and (vi) severely ill people should not take LF drugs. Low level of knowledge is assigned to those scoring less than median of the distribution and
high level of knowledge is assigned to those scoring the same as median or above
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(i) it is a single disease programme, rather than an
integrated NTD programme; (ii) drug delivery for LF is
carried out together by health personnel and cadres rather
than largely by volunteer drug distributors; (iii) mass drug
administration for LF is not integrated with any other
NTD activities. Note that other NTDs present in
Indonesia include: schistosomiasis, leprosy, yaws, scabies
and soil-transmitted helminths. The high burden of soil-
transmitted helminths (STH) in some parts of Indonesia
warrants inclusion of promoting treatment of STH during
MDA for LF [23].
This research provides some insights into the know-
ledge of deliverers working in the Indonesian LF
programme by exploring three knowledge attributes of
those involved in the delivery of the LF drugs during
MDA, specifically related to: (i) lymphatic filariasis; (ii)
the mass drug administration; and (iii) coverage and
compliance results (MDA feedback) within the deliverer’s
Fig. 4 Perceived number of people receiving and taking LF drugs
Fig. 5 Level of knowledge about LF and MDA, and MDA feedback by type of drugs deliverers
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location. Each of these three areas will be discussed within
the context of the broader literature.
There were varied levels of knowledge about LF amongst
the three different groups of deliverers approached: com-
munity leaders, cadres and health workers. Overall, health
workers have a higher level of knowledge than cadres,
which may be expected. Community and religious leaders
however have much less knowledge than cadres. These in-
dividuals may not be routinely included in the regular cadre
training and may not even receive formal training. They
are, however, important spokespeople for the programme
within the community and play a crucial role in mobilising
the community and encouraging people to take the LF pills.
When drug deliverers and community promoters are not
well informed, there is a risk that incorrect information
may be transmitted, conflicting with information from the
health services. This discrepancy risks to undermine com-
munity confidence in both the deliverer and the MDA
process itself. We know from other contexts that commu-
nity confidence is important to encourage compliance with
the treatment. In Sri Lanka, Gunawardena et al. [24] re-
ported that people were unhappy to take the LF drugs from
the distributors when there was inadequate information.
Weerasooriya et al. [25] remarked that people did not have
confidence in some of the distributors, thus effecting com-
pliance in the community under study. In India, Ramaiah
at al. [22, 26] showed that the community had poor confi-
dence in the distributors. Our study shows that those who
have more experience with MDA (> 3 times) have higher
levels of knowledge than those who have participated less
Table 3 Frequency distribution of drugs deliverers in MDA according to their knowledge about LF and MDA as well as MDA
feedback by district
Variable District
Agam District Depok City Batam City
(N = 109) (N = 107) (N = 102)
n % 95% CI n % 95% CI n % 95% CI
A. Knowledge about lymphatic filariasis (LF)
Knowledge of LFa
Low 54 49.5 40.2–58.9 58 54.2 44.7–63.5 76 74.5 65.1–82.1
High 55 50.5 41.1–59.8 49 45.8 36.5–55.4 26 25.5 17.9–34.9
B. Knowledge about MDA
Knowledge about MDAb
Low 54 49.5 40.2–58.9 58 54.2 44.7–63.5 71 69.6 59.9–77.8
High 54 49.5 40.2–58.9 49 45.8 36.5–55.4 31 30.4 22.2–40.1
C. MDA feedback
Informed about the number receiving or taking LF drugs
No 56 51.4 42.0–60.7 22 20.6 13.9–29.3 32 31.4 23.1–41.1
Yes 53 48.6 39.3–58.0 85 79.4 70.7–86.1 70 68.6 58.9–76.9
D. Other
Perceived adequacy of knowledge to carry out roles and responsibilities in MDA
Inadequate 10 9.2 5.0–16.3 9 8.4 4.4–15.5 9 8.8 4.6–16.2
Neutral 8 7.4 3.7–14.1 17 15.9 10.1–24.2 25 24.5 17.1–33.9
Adequate 91 83.5 75.2–89.4 81 75.7 66.6–83.0 68 66.7 56.9–75.2
Perception about training received prior to MDA
Very informative 22 20.2 13.6–28.8 59 55.1 45.6–64.4 36 35.3 26.6–45.1
Informative 68 62.4 52.9–71.0 38 35.5 27.0–45.1 46 45.1 35.7–54.9
Less informative 7 6.4 3.1–12.9 4 3.7 1.4–9.6 18 17.7 11.4–26.4
No training 12 11.0 6.3–18.5 6 5.6 2.5–12.0 2 2.0 0.5–7.6
aKnowledge about LF is based on three variables: (i) know that worm is the cause of LF; (ii) know that mosquitoes transmit LF; and (iii) know that LF is
preventable. Low level of knowledge is assigned to those scoring less than median of the distribution and high level of knowledge is assigned to those scoring
the same as median or above
bKnowledge about MDA is based on six variables: knowledge that (i) all LF drugs should be taken; (ii) pregnant women should not take LF drugs; (iii) children
under two years old should not take LF drugs; (iv) severely undernourished children should not take LF drugs; (v) people aged more than 75 years old should not
take LF drugs; and (vi) severely ill people should not take LF drugs. Low level of knowledge is assigned to those scoring less than median and high level of
knowledge is assigned to those scoring the same as median or above
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than 3 times. This suggests that repeated exposure to train-
ing may impact knowledge and understanding. Training
that is tailored to the level of experience of the deliverer is
recommended so that those participating in MDA for the
first few rounds might receive more detailed instruction
and supervision than those who have been part of the
MDA programme for years.
Of our three research sites, Batam City consistently
scored lower on LF knowledge and perception of training
in relation to the other sites. We posit that there are several
Table 4 Multivariate analysis on factors associated with knowledge about LF and MDA and MDA feedback
Variable High level of knowledge about LFa High level of Knowledge about MDAb Received MDA feedbackc
aOR 95% CI P-value aOR 95% CI P-value aOR 95% CI P-value
A. Socio demographic characteristics
District/City
Agam District 1.00 1.00 1.00
Depok City 0.89 0.46–1.70 0.720 1.03 0.57–1.86 0.922 5.08 2.53–10.17 < 0.001
Batam City 0.39 0.18–0.85 0.017 0.62 0.31–1.24 0.175 2.54 1.33–4.86 0.005
Age
≤ 35 1.00 1.00 1.00
36–45 1.46 0.71–2.98 0.301 0.71 0.37–1.37 0.309 1.77 0.86–3.67 0.123
46–55 0.83 0.39–1.79 0.643 0.31 0.15–0.64 0.002 1.92 0.87–4.25 0.107
Sex
Male 1.00
Female 2.68 1.07–6.75 0.036
B. Role and frequency of participation in MDA
Role of respondent during MDA
Cadre 1.00 1.00 1.00
Community/religious leaders 0.57 0.30–1.08 0.086 0.66 0.36–1.21 0.178 0.95 0.41–2.21 0.904
Health workers 6.47 3.03–13.83 <0.001 2.68 1.40–5.14 0.003 9.01 3.32–24.44 < 0.001
Frequency of participation in MDA
1–3 times 1.00 1.00
> 3 times 2.42 1.26–4.71 0.008 2.10 1.12–3.92 0.021
C. Knowledge and training to perform in MDA
Perceived adequacy of knowledge to conduct their tasks and responsibility in MDA
Inadequate 1.00
Neutral 8.26 2.55–26.74 < 0.001
Adequate 6.72 2.48–18.22 < 0.001
Perception about training prior to MDA
Very informative 1.00
Informative 1.31 0.73–2.36 0.371
Less informative 1.43 0.52–3.97 0.491
No training 0.21 0.05–0.84 0.027
aOther variables included in the analysis but were removed in multivariate analysis: sex, education, length of stay, work with other during MDA, perceived
adequacy of knowledge to carry out roles and responsibilities in MDA. Knowledge about LF is based on three variables: (i) know that worm is the cause of LF; (ii)
know that mosquitoes transmit LF; and (iii) know that LF is preventable. Low level of knowledge is assigned to those scoring less than median of the distribution
and high level of knowledge is assigned to those scoring the same as median or above
bOther variables included in the analysis but were removed in multivariate analysis: sex, education, length of stay, work with other during MDA, perceived
adequacy of knowledge to carry out roles and responsibilities in MDA, perception about training received prior to MDA. Knowledge about MDA is based on six
variables: knowledge that (i) all LF drugs should be taken; (ii) pregnant women should not take LF drugs; (iii) children under two years old should not take LF
drugs; (iv) severely undernourished children should not take LF drugs; (v) people aged more than 75 years old should not take LF drugs; and (vi) severely ill
people should not take LF drugs. Low level of knowledge is assigned to those scoring less than median of the distribution and high level of knowledge is
assigned to those scoring the same as median or above
cOther variables included in the analysis but were removed in multivariate analysis: education; length of stay; work with other during MDA; perception about
training received prior to MDA; knowledge of LF; and knowledge about MDA, and frequency of participation in MDA Abbreviation: aOR Adjusted odds ratio
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reasons for this difference: the urban nature of Batam City
and the challenges inherent in MDA programs in these
areas; systemic issues within the local LF program that
require further investigation; and the measurement of
Depok and Agam deliverers was conducted after a year of
enhanced MDA activity by the DHO. The other urban area
in our study, Depok City, is part of the greater Jakarta
metropolitan area, and so may benefit from higher expos-
ure to the LF programme in terms of support and materials
thereby differentiating it from Batam.
In our study, deliverers seem to recognise the coverage-
compliance gap as seen in their perceptions of how many
community members received drugs versus those who
they perceived had swallowed the pills. Babu & Babu [12]
used the term “coverage-compliance” gap to explain the
inconsistency between the recorded distributed drugs and
those drugs that are ingested. This reflects the common
digression from the gold standard practice of directly ob-
served treatment (DOT) whereby individuals are expected
to swallow the LF drugs in front of the deliverer [27]. In
Indonesia, over time, the practice of DOT is not routinely
followed by drug deliverers. As a result, coverage results
do not always reflect consumed drugs. Our study showed
that the deliverers themselves perceive this gap between
coverage and compliance as revealed in the discrepancy
between their perception of drugs distributed and drugs
consumed. Any improvements to the MDA program will
need to address poor adherence of drug deliverers to the
standard of DOT. To support this, the manner of distribu-
tion will need to be assessed (house to house versus distri-
bution posts), the perception of community members on
the need to take treatment before bed as well as the need
to eat before swallowing pills and improved supervision
during MDA. These factors can impede the direct obser-
vation of drug ingestion in front of drug deliverers as has
been shown in Indian studies where DOT has not been
ensured [28–30].
The study participants had a surprisingly low score for
knowledge about mass drug administration, particularly
when it concerned the eligibility of individuals. This may
be the result of some of the Indonesian ELF program
changes on eligibility over time, particularly with regards
to breastfeeding women and elderly persons. Particularly
concerning was the poor overall knowledge of the ineligi-
bility of children under two years old and undernourished
children. In the published literature, evidence shows that
communities perceive when deliverer knowledge with
regards to eligibility is inadequate. In India, community
members reported that they lacked confidence in the
distributors’ ability to assess eligibility for DEC during the
MDA [31]; and in another Indian study [30] community
members reported that distributors were confused and
gave inadequate amounts of the LF drugs. In addition to
the effect on community perceptions and confidence in
the distributor, there are also concerns with regards to
misallocated treatment to individuals who are ineligible
for treatment. Our results show that the longer deliverers
are involved with the MDA program, the more likely they
are to have better understanding about eligibility for
MDA. This suggests that programmes need to focus on
retaining the delivery workforce so as to build and capital-
ise on their knowledge and experience.
While participants had a low knowledge scores for
MDA, they perceived that their knowledge is sufficient for
the implementation of their work. In Agam District, this
was stronger than in the other two more urban areas. The
process of mass drug administration lends itself more to a
rural or semi-rural environment, such as Agam, where
cadres are usually active in the population and known to
their communities. The content of the training and the
application of MDA by community volunteers may be
more appropriate for these contexts, rather than the urban
environments of Batam and Depok where cadres may not
be known in the population, where the community is
more diverse and where population movement is more
common place. These factors have been explored in other
research related to MDA within urban settings [32–34]. In
short, these results suggest that the Agam deliverers feel
more confident in their MDA activities as the training
may be more appropriate to their semi-rural and rural
contexts. Achieving sufficient drug coverage in urban
MDA programs remains a key challenge to the global pro-
gram and our study suggests that renewed training would
be an area for intervention [35].
This research is not without its limitations. One of the
challenges in assessing drug deliverers is establishing a
reliable outcome measurement. Because performance-
based measurements are not usually carried out for drug
deliverers, any variable of success in activities will be
subjective to the individual deliverer. If the deliverer
reports success, can this be considered an accurate and
real measurement? Furthermore, as the literature has
stated [12], the coverage-compliance gap remains an
important concern in the delivery of the LF drugs and as
a result, these perceptions of success as measured in
drugs delivered may not actually represent drugs
consumed. So although our three outcomes of measure-
ment, (i) knowledge about LF; (ii) knowledge about
MDA; and (iii) MDA feedback, may not be the most
appropriate measurements of performance of drug deliv-
erers, they nevertheless can serve as proxy indicators for
the training activities, supervision and evidence of the
feedback loop in program monitoring and evaluation.
Because purposive sampling was used to identify
individuals, it is possible that some bias may have been
introduced in the selection of individuals, although every
effort was made to minimize any bias. The authors pro-
vided a matrix for each study site to ensure that a range
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of informants were identified. The study teams in each
site followed this matrix closely.
Conclusions
Our research demonstrates that there are variations in
knowledge about LF and MDA as well as MDA feedback
across the three different kinds of people involved with
MDA delivery in Indonesia: the health personnel, cadres
and community leaders. Although it is expected that
there would be certain differences in between groups,
these variations may also reflect differences in the train-
ing programmes prior to MDA as well as active supervi-
sion during the MDA process. Some of these variations
are also seen in between the urban (Depok City and
Batam) and the rural (Agam) sites of this research. The
knowledge as well as level of confidence of the deliverer
is different in the urban areas than in the rural location
of the research, suggesting that the MDA platform may
be more suitable for rural populations. Increased years
of experience are related to higher levels of knowledge
about LF and MDA suggesting that retaining the existing
workforce is of paramount importance. Our research
suggests some recommedations to improve the perform-
ance of drug deliverers. First, urgent action is required
to solidify knowledge about eligibility across all groups
working to promote and distribute LF drugs during
MDA. Secondly, current guidelines for MDA can be
adapted to an urban environment, in particular, updating
deliverer training and promotional activities. Supportive
supervision in these environments may help to motivate,
increase confidence and build the skills of cadres in
these locations. Thirdly, supporting materials and/or
shortened training for community leaders, particularly in
low performing areas will be beneficial to increase
awareness and participation during MDA. Finally, regular
assessments of the deliverer workforce is important to
detect any fluctuations in knowledge amongst these
individuals, due to turnover or lack of training. Training
programmes need to reflect the level of experience and
knowledge of deliverers, considering the different needs of
those participating for the first time. Due to the long term
nature of the LF elimination program, it is important that
programs actively assess and aid these key individuals,
retaining this key workforce.
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